Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymosins: structure, function and therapeutic applications.

T L Low, A L Goldstein

    Thymus
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Maternal and neonatal outcome of women before vs. after bariatric surgery: A single tertiary center experience.

    American journal of surgery·2022
    Same author

    eTEP inferior access with tailored retromuscular dissection for small to mid-sized umbilical hernia repair with or without inguinal hernia: early experience.

    Hernia : the journal of hernias and abdominal wall surgery·2022
    Same author

    How-we-do-it: the repair of postoperative ventral hernias after a Mercedes abdominal incision.

    Langenbeck's archives of surgery·2021
    Same author

    Successful management of the open abdomen with hydrocolloid dressing in a resource-constrained setting.

    Hernia : the journal of hernias and abdominal wall surgery·2020
    Same author

    ACTUALITIES IN ENDOCRINOLOGY- PARATHYROID IMAGING.

    Acta endocrinologica (Bucharest, Romania : 2005)·2019
    Same author

    Cryptogenic stroke in hanging. A case report.

    The neuroradiology journal·2013
    Same journal

    Detection of Fas and its ligand, FasL, in mouse thymus by in situ hybridization.

    Thymus·1997
    Same journal

    Nonresponsiveness and susceptibility to CTLA-4 of antigen-exposed CD4 T cells are not regulated by the Bcl-2 family of apoptotic mediators, but can be restored by IL-2.

    Thymus·1997
    Same journal

    Modulation of cytokine gene expression by thymic lympho-stromal cell to cell interaction: effect of retinoic acid.

    Thymus·1997
    Same journal

    Anti-NK antibodies injected into recipient mice enhance engraftment and chimerism after allogeneic transplantation of fetal liver stem cells.

    Thymus·1997
    Same journal

    Presence of nerve growth factor in the thymus of prenatal, postnatal and pregnant rats.

    Thymus·1997
    Same journal

    Loss of T-cell cytotoxic responses in the course of HIV-1 infection.

    Thymus·1997
    See all related articles

    Thymosin fraction 5 effectively corrects immunological deficiencies in humans and animal models. Research is ongoing to understand its therapeutic potential for immunodeficiency, autoimmune diseases, and cancer.

    Area of Science:

    • Immunology
    • Endocrinology
    • Molecular Biology

    Background:

    • Thymosin, a hormone crucial for T-cell development, is essential for normal immune function.
    • Deficiencies in thymosin function lead to various immunological deficits in both animal models and humans.
    • Thymosin fraction 5 is a partially purified preparation containing multiple biologically active peptides.

    Purpose of the Study:

    • To investigate the therapeutic potential of thymosin fraction 5 in correcting immunological deficiencies.
    • To identify and characterize the specific thymic peptides responsible for restoring immune function.
    • To evaluate the efficacy of thymosin fraction 5 and its components in clinical settings.

    Main Methods:

    • Partially purified thymosin fraction 5 was used to treat individuals with immunological deficiencies.

    Related Experiment Videos

  • Biologically active peptides within thymosin fraction 5 were purified to homogeneity.
  • Two key peptides, thymosin alpha 1 and thymosin beta 4, were sequenced and chemically synthesized.
  • Clinical trials were initiated using thymosin fraction 5 and synthetic thymosin alpha 1.

    • Main Results:

    • Thymosin fraction 5 demonstrated the ability to correct numerous immunological deficiencies.
    • Purification and sequencing identified specific peptides, including thymosin alpha 1 and beta 4, with immunomodulatory activity.
    • Clinical trials involving patients with immunodeficiency, autoimmune diseases, and cancer showed encouraging preliminary results.
    • The National Cancer Institute has launched new trials investigating thymosin fraction 5 and synthetic alpha 1 as biological response modifiers.

    Conclusions:

    • Thymosin fraction 5 contains a family of peptides that can restore T-cell function and immunological reactivity.
    • Synthetic thymosin alpha 1 and thymosin fraction 5 hold promise as therapeutic agents for a range of immune-related conditions.
    • Further clinical investigation is warranted to fully establish the therapeutic benefits of thymosin-based therapies.